Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. NASDAQ:REGN | $98.82B | $955.47 | Undervalued | 14.2 | +35.08% |
Bausch + Lomb Corporation NYSE:BLCO | $7.54B | $21.09 | Overvalued | -24.2 | +43.30% |
Belite Bio, Inc NASDAQ:BLTE | $6.62B | $164.36 | Not rated | -65.9 | +29.79% |
Ocular Therapeutix, Inc. NASDAQ:OCUL | $1.37B | $6.21 | Not rated | -7.3 | -50.91% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | -3.15% |
Oculis Holding AG NASDAQ:OCS | $471.63M | $7.64 | Not rated | -5.5 | -61.65% |
Ocugen, Inc. NASDAQ:OCGN | $280.88M | $0.83 | Not rated | -5.6 | -35.16% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -79.19% |
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | $25.66M | $0.31 | Not rated | -4.2 | -79.06% |
Continue the stock analysis
Jump to another research area for this company.